MediciNova Heads to ROTH, Puts Late-Stage Pipeline in Investor Spotlight

LA JOLLA, Calif. – March 16, 2026 – Clinical-stage biopharmaceutical company MediciNova, Inc. (NASDAQ: MNOV) is preparing for a crucial series of investor meetings at the upcoming 38th Annual ROTH Conference in Dana Point, California. From March 22-24, the company’s leadership, including President and CEO Yuichi Iwaki, M.D., Ph.D., and Chief Business Officer David H. Crean, Ph.D., will engage in one-on-one discussions to articulate the value and progress of its ambitious late-stage pipeline.

For a company like MediciNova, which trades at a modest market capitalization but harbors significant clinical assets, events like the ROTH Conference are more than just a calendar entry; they are a vital platform. It's an opportunity to move beyond press releases and SEC filings, providing the direct, high-touch engagement that institutional investors require as they weigh the potential rewards against the inherent risks of drug development.

The Investor Pitch: High Stakes for a Promising Pipeline

MediciNova arrives at the conference with a story that is compelling on paper but requires the conviction of face-to-face dialogue. The company focuses on developing small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases—areas with profound unmet medical needs. While the company's stock has hovered in a range between $1.13 and $1.96 over the past year, closing recently at $1.36, Wall Street analysts see a vastly different picture. Consensus price targets sit in a range of $8.00 to $11.00, suggesting a deep disconnect between the current valuation and the perceived potential of its drug candidates.

Investors attending the meetings will undoubtedly probe Drs. Iwaki and Crean on how the company plans to bridge this valuation gap. Key topics will likely include the company's financial footing and strategic path to commercialization. MediciNova recently reported a smaller-than-expected quarterly loss and, according to a February 8-K filing, possesses a cash runway sufficient to fund operations into 2027. This financial stability is further supported by a Standby Equity Purchase Agreement (SEPA) for up to $30 million, providing flexible access to capital. These points will be critical for reassuring investors that the company is well-positioned to execute on its upcoming clinical milestones without imminent financial distress.

Spotlight on MN-166: A Multi-Pronged Attack on Neurodegeneration

At the heart of MediciNova's investor pitch is its lead asset, MN-166 (ibudilast), a versatile compound being investigated for a host of debilitating conditions. The most anticipated program is for amyotrophic lateral sclerosis (ALS), a relentlessly progressive and fatal neurodegenerative disease.

Enrollment for the pivotal Phase 2b/3 COMBAT-ALS trial was completed in September 2025, a significant operational achievement. With 234 participants randomized, the company is now on a clear path toward a major data readout, with top-line results expected by the end of 2026. This single event represents a potentially company-defining catalyst. Adding to the program's credibility, a separate Expanded-Access-Program (EAP) for ALS patients is supported by a substantial $22 million grant from the National Institutes of Health (NIH), underscoring the scientific community's interest in MN-166's potential.

Beyond ALS, MN-166 is poised to address other significant neurological disorders. The drug is designated as Phase 3-ready for progressive forms of multiple sclerosis (MS), another area where treatment options are limited and the disease burden is high. Furthermore, a Phase 3 trial is already underway for degenerative cervical myelopathy (DCM), a common cause of spinal cord dysfunction. The compound’s utility is also being explored in Phase 2 trials for Long COVID and substance dependence, demonstrating a broad therapeutic window that could unlock substantial future value.

Beyond Neurodegeneration: Targeting Fibrosis and Metabolic Disease

While MN-166 rightly captures much of the attention, MediciNova's second asset, MN-001 (tipelukast), presents another near-term opportunity for a significant value inflection. The company is advancing this compound in a Phase 2 trial for patients with non-alcoholic fatty liver disease (NAFLD), Type 2 diabetes, and hypertriglyceridemia. Enrollment for this study was completed in November 2025, and investors will be keenly awaiting the top-line data, which is anticipated in the summer of 2026.

NAFLD, recently reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), is a silent epidemic affecting a vast global population with no currently approved therapies. A positive data readout in this indication could be transformative for MediciNova, opening up a massive commercial market. MN-001 has also completed a Phase 2 trial for idiopathic pulmonary fibrosis (IPF), another progressive and fatal fibrotic disease, further diversifying the company's clinical portfolio against diseases characterized by inflammation and scarring.

Navigating a Crowded and Competitive Landscape

MediciNova's ambitious programs do not exist in a vacuum. The therapeutic areas it targets are some of the most competitive and challenging in modern medicine. The ALS pipeline, for instance, is bustling with over 70 companies developing more than 80 different therapies, from gene therapies to novel small molecules. Similarly, in progressive MS, MediciNova's MN-166 will have to contend with a new generation of powerful BTK inhibitors being developed by pharmaceutical giants like Sanofi and Roche.

The landscape for NAFLD/MASLD is equally intense, with numerous companies vying to be the first to market with an approved drug. Even large-cap players are entering the fray, with antidiabetic agents like GLP-1 agonists showing promising effects on liver health. The ROTH meetings will provide a forum for MediciNova’s leadership to articulate their strategy and explain how their compounds’ unique mechanisms of action and strong safety profiles can carve out a meaningful niche in these crowded fields.

For MediciNova, the path forward is defined by a series of high-impact data readouts. The meetings at the ROTH Conference represent a critical opportunity to set the stage, manage expectations, and build the investor confidence necessary to see its promising pipeline through these pivotal final stages of development. With major catalysts on the horizon for both ALS and NAFLD in 2026, the conversations in Dana Point could lay the groundwork for a transformative year for the company.